スギモト　ナオキ   Sugimoto Naoki   杉本　直樹    所属   医学部 医学科（東京女子医科大学病院）    職種   非常勤講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Trends in Risks of Malignancies in Japanese Patients with Rheumatoid Arthritis: Analyses from a 14-year Observation of the IORRA Cohort.
掲載誌名	正式名：Modern rheumatology 略　 称：Mod Rheumatol ISSNコード：14397609/14397595
巻・号・頁	pp.-
著者・共著者	Sugimoto Naoki, Tanaka Eiichi, Inoue Eisuke, Abe Mai, Sugano Eri, Sugitani Naohiro, Saka Kumiko, Ochiai Moeko, Higuchi Yoko, Yamaguchi Rei, Ikari Katsunori, Nakajima Ayako, Yamanaka Hisashi, Harigai Masayoshi
担当区分	筆頭著者
発行年月	2022/08/03
概要	OBJECTIVES:To investigate the trends in risks of overall and site-specific malignancies in patients with rheumatoid arthritis (RA).METHODS:Among Japanese patients with RA enrolled in the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) cohort, all malignancies that occurred from 2000 to 2013 were extracted. The standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for overall and site-specific malignancies were calculated during three periods: pre-biologics, 2000-2004; early biologics, 2005-2009; and recent biologics, 2010-2013. Risk factors for overall and specific malignancies were analyzed using time-dependent Cox regression models.RESULTS:Among 11,299 patients with RA (68,483 person-years), 507 malignancies were confirmed. Similar risks were observed versus the general Japanese population for overall malignancies throughout the three periods, with SIRs (95% CIs) of 0.96 (0.80-1.14) in the pre-biologics period, 0.95 (0.82-1.09) in the early biologics period, and 0.87 (0.75-1.01) in the recent biologics period. Significant increased risk for malignant lymphoma was observed throughout the observation period (SIR 4.61, 95% CI 3.58-5.85). The disease activity was a significant risk factor for overall malignancies and lung cancer.CONCLUSION:Despite the expanding use of methotrexate and biologics, there were no increases in malignancy risk in Japanese patients with RA.
DOI	10.1093/mr/roac085
PMID	35920098